Status:
COMPLETED
Comparing 18F-FAPI-04 and 18F-FDG PET/CT in Cancer Detection
Lead Sponsor:
Lanzhou University Second Hospital
Conditions:
Malignant Neoplasm
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Evaluating fluoro-18-fibroblast activation protein inhibitor-04 positron emission computed tomography's diagnostic efficacy for primary malignancies versus 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxygl...
Detailed Description
In recent years, radionuclide labeled fibroblast activating protein inhibitors (FAPIs) have gradually become a new strategy for targeted diagnosis and therapy. In this study, radionuclide 18F was used...
Eligibility Criteria
Inclusion
- Adult (≥18 years old); PET/CT examination is required after evaluation by oncologist. Healthy persons who volunteer for PET/CT scans; Can cooperate to complete the inspection process; I or family members, legal representatives agree to participate in the study and can sign the informed consent in person.
Exclusion
- The patient has a serious underlying disease or mental illness and is unable to cooperate with the PET/CT examination; Have received systematic chemotherapy; Previous history of primary tumor; Pregnancy; I or family members, legal representatives are unable or unwilling to provide written informed consent.
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT06206642
Start Date
April 1 2022
End Date
December 31 2023
Last Update
January 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Hospital of Lanzhou University
Lanzhou, Gansu, China, 730030